Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2011

PanOptica Raises $30M in Series A and Licenses Neovascular AMD Candidate

  • Ophthalmology firm PanOptica raised $30M in a Series A financing round, and acquired worldwide ophthalmic rights to a clinical-stage small molecule selective VEGF inhibitor from OSI Pharmaceuticals. The Series A financing was led by SV Life Sciences and Third Rock Ventures.

    The newly acquired drug candidate, designated PAN-90806, will be developed as a topical treatment for neovascular age-related macular degeneration (neovascular AMD), a disorder which PanOptica points out is currently treated using anti-VEGF injections into the eye. PAN-90806 has previously been evaluated in clinical studies for oncology indications, and in preclinical studies in ocular angiogenesis models, topically administered PAN-90806 suppressed the formation of new blood vessels, PanOptica points out. The firm projects starting a Phase I clinical study for the ophthalmology indication during 2012.

    Established in 2009, PanOptica’s goal is to acquire IND or near-IND stage assets and mature them to clinical proof of concept. The Series A investment will allow the firm to push on with clinical trials and expand its pipeline, notes Paul Chaney, co-founder, president, and CEO at PanOptica. “We’re thrilled to have completed our Series A financing, which enables us to advance PAN-90806 through Phase II clinical trials, complete a licensing deal for a second compound and develop it through Phase II, and select a third asset, which we’re actively seeking.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »